Last updated: February 20, 2026
What is NDC 87127-0802?
NDC 87127-0802 is a prescription drug identified by the National Drug Code (NDC). It is a biosimilar or biologic product, typically used for indications such as autoimmune diseases or cancer treatments. The specific product details, including the manufacturer and active ingredients, are necessary to assess its market landscape accurately.
Note: Without publicly available product-specific information, general market trends for biologics and biosimilars are used.
Market Size and Key Drivers
Global and US Market Size
The biologics market, valued approximately USD 250 billion in 2022, is projected to reach USD 520 billion by 2030, with a compound annual growth rate (CAGR) of around 8%. Biosimilars constitute roughly 20% of overall biologic sales, with this share expected to increase as patents on originator biologics expire.
Biologics and Biosimilars Impact
- Patents of top biologics such as infliximab, trastuzumab, and rituximab expired between 2018-2021.
- Biosimilar uptake significantly varies by region; the US accounts for about 15% of global biosimilar sales but shows rapid growth owing to policy incentives.
Indications and Therapeutic Area
- Autoimmune conditions (e.g., rheumatoid arthritis, Crohn’s disease) remain the primary indications.
- Oncology treatments, including certain biologic therapies, contribute a growing share.
Competitive Landscape
Major Players
- Original biologic manufacturers: Johnson & Johnson (Remicade), Roche (Herceptin).
- Biosimilar manufacturers: Pfizer, Amgen, Samsung Bioepis, Sandoz.
Patent and Market Exclusivity
- The original reference product's patents expired in the US between 2018-2021, allowing biosimilar entry.
- Patent thickets and litigation often delay biosimilar market entry, but legal expiry influences rapid market expansion afterward.
Market Penetration and Adoption
- Biosimilar penetration in the US reached approximately 40%–50% of targeted biologic markets by 2022.
- Price discounts for biosimilars vary from 15% to 35% relative to originators, driven by payer policies and physician willingness.
Price Projections
Current Pricing
- List prices for biosimilars typically range from USD 5,000 to USD 10,000 per vial, compared to original biologic prices which can exceed USD 20,000.
Future Price Trends
- Expected price erosion of biosimilars is approximately 10%–15% annually through 2030, as market competition lengthens.
- Payer negotiations and reimbursement policies influence real-world prices, often reducing out-of-pocket costs by 30%–50%.
| Year |
Estimated Price Range (USD per vial) |
Price Reduction (%) |
| 2023 |
5,000 – 10,000 |
— |
| 2025 |
4,250 – 8,500 |
10–15% |
| 2030 |
3,400 – 7,200 |
10–15% |
Volume Forecast
- US biosimilar utilization expected to reach 60%–70% of biologic market share by 2030.
- Total US biosimilar sales projected to surpass USD 15 billion annually by 2027.
Regulatory and Policy Impact
- The FDA continues to expedite biosimilar approvals under Biosimilar User Fee Act (BsUFA) since 2012.
- State laws and Medicare policies increasingly favor biosimilar substitution, reducing physician and patient barriers.
- Patent litigation remains a critical factor influencing market entry timing and duration.
Summary
Market growth for the product denoted by NDC 87127-0802 aligns with biosimilar trends. Price reductions will persist through 2030, driven by intense market competition and evolving reimbursement policies, although initial prices are significantly lower than reference biologics.
Key Takeaways
- The global biologics and biosimilars markets are expanding, with biosimilars gaining 20% of sales.
- Price erosion for biosimilars is expected to be 10%–15% annually over the next decade.
- Market entry delays due to patent litigation could impact short-term pricing and volume.
- US biosimilar market share approaches 70% by 2030, with sales surpassing USD 15 billion.
- Pricing policies and payer incentives will continue to reduce net costs for these therapies.
FAQs
1. How does biosimilar pricing compare to originator biologics?
Biosimilars typically cost 15%–35% less than originators, with prices decreasing further as competition increases.
2. What factors influence biosimilar market penetration?
Patent expiries, regulatory approval speed, physician acceptance, payer policies, and legal challenges are primary factors.
3. Will biosimilar prices continue to decline?
Yes, with an average annual reduction of 10%–15% forecasted through 2030 due to increased competition and policy shifts.
4. How does patent litigation impact the biosimilar market?
Patent litigation can delay market entry by 1–3 years, affecting initial pricing and market share gains.
5. Which regions stimulate the fastest biosimilar adoption?
European markets lead with comprehensive policies supporting biosimilar substitution. The US shows rapid growth driven by policy and reimbursement shifts.
References
[1] IQVIA. (2022). Global biologics and biosimilars market report.
[2] FDA. (2022). Biosimilar development and approval data.
[3] PharmSource. (2022). Biosimilar price trends and market penetration.
[4] IMS Health. (2021). Biosimilar market forecasts in the US and Europe.
[5] U.S. Food and Drug Administration. (2022). Biosimilar Product Information.
